Dealmaking: Is the Irrationality Inevitable?
Big Pharma contends it's making in-licensing more transparent and strategic, while some biotechs complain about continuing dealmaking roulette.
You may also be interested in...
Sandoz and Civica Rx have entered into a long-term collaboration to help mitigate medicine shortages in US hospitals, where Sandoz will supply six critical injectables and Civica will ensure reliable supply of these medicines to patients.
US major continues its expansion in oncology with an early stage deal with Flagship Pioneering protegés.
Centrient has declared itself one of the first companies to announce progress in achieving Predicted No-Effect Concentration discharge targets for the largest part of its antibiotics – the firm’s semi-synthetic penicillin active pharmaceutical ingredients portfolio. In addition, 97% of Centrient’s SSP finished-dose formulation products are also PNEC compliant, according to the firm.